"xaliproden" meaning in English

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "xaliproden (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2017 November 14, Angeles Canales, Biophysical Techniques in Drug Discovery, Royal Society of Chemistry, page 141",
          "text": "... xaliproden Forms I and III mostly concerns the degree of freedom of the CF3 group, higher in Form III than in Form I, and they clarified the status of Form III, which could then be assigned to a well-defined polymorph of xaliproden. In[…]",
          "type": "quotation"
        },
        {
          "ref": "2000, Mark B. Bromberg, Supplements to Clinical Neurophysiology",
          "text": "... xaliproden with and without riluzole . Data analysis is ongoing and will be the subject of a future publication ... xaliproden (1 mg/day) plus riluzole; xaliproden (2 mg/day) alone or xaliproden (2 mg/day) plus[…]",
          "type": "quotation"
        },
        {
          "ref": "2008 April 15, P. Murali Doraiswamy, M.D., Lisa P. Gwyther, M.S.W., Tina Adler, The Alzheimer's Action Plan: The Experts' Guide to the Best Diagnosis and Treatment for Memory Problems, St. Martin's Press, page 173",
          "text": "... Xaliproden. As with the drug cerebrolysin discussed above, xaliproden mimics the actions of NGFs. It was initially studied without success in Lou Gehrig's disease, a condition, like Alzheimer's, that involves progressive brain damage[…]",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A drug which acts as a 5HT1A agonist, proposed for use in the treatment of several neurodegenerative conditions including Alzheimer's disease."
      ],
      "id": "en-xaliproden-en-noun-qvl6Qmal",
      "links": [
        [
          "drug",
          "drug"
        ],
        [
          "agonist",
          "agonist"
        ],
        [
          "neurodegenerative",
          "neurodegenerative"
        ],
        [
          "Alzheimer's disease",
          "Alzheimer's disease"
        ]
      ],
      "tags": [
        "uncountable"
      ],
      "wikipedia": [
        "xaliproden"
      ]
    }
  ],
  "sounds": [
    {
      "ipa": "/zəˈlɪpɹədɛn/"
    }
  ],
  "word": "xaliproden"
}

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "xaliproden (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry"
      ],
      "examples": [
        {
          "ref": "2017 November 14, Angeles Canales, Biophysical Techniques in Drug Discovery, Royal Society of Chemistry, page 141",
          "text": "... xaliproden Forms I and III mostly concerns the degree of freedom of the CF3 group, higher in Form III than in Form I, and they clarified the status of Form III, which could then be assigned to a well-defined polymorph of xaliproden. In[…]",
          "type": "quotation"
        },
        {
          "ref": "2000, Mark B. Bromberg, Supplements to Clinical Neurophysiology",
          "text": "... xaliproden with and without riluzole . Data analysis is ongoing and will be the subject of a future publication ... xaliproden (1 mg/day) plus riluzole; xaliproden (2 mg/day) alone or xaliproden (2 mg/day) plus[…]",
          "type": "quotation"
        },
        {
          "ref": "2008 April 15, P. Murali Doraiswamy, M.D., Lisa P. Gwyther, M.S.W., Tina Adler, The Alzheimer's Action Plan: The Experts' Guide to the Best Diagnosis and Treatment for Memory Problems, St. Martin's Press, page 173",
          "text": "... Xaliproden. As with the drug cerebrolysin discussed above, xaliproden mimics the actions of NGFs. It was initially studied without success in Lou Gehrig's disease, a condition, like Alzheimer's, that involves progressive brain damage[…]",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A drug which acts as a 5HT1A agonist, proposed for use in the treatment of several neurodegenerative conditions including Alzheimer's disease."
      ],
      "links": [
        [
          "drug",
          "drug"
        ],
        [
          "agonist",
          "agonist"
        ],
        [
          "neurodegenerative",
          "neurodegenerative"
        ],
        [
          "Alzheimer's disease",
          "Alzheimer's disease"
        ]
      ],
      "tags": [
        "uncountable"
      ],
      "wikipedia": [
        "xaliproden"
      ]
    }
  ],
  "sounds": [
    {
      "ipa": "/zəˈlɪpɹədɛn/"
    }
  ],
  "word": "xaliproden"
}